MedTrace Logo

Activation Innate Immune System in Type 1 Diabetes

NCT03441919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2019-04-02

No results posted yet for this study

Summary

Hyperglycemia is a well-known cardiovascular risk factor. It has also been shown that episodes of hyperglycemia increase the risk for cardiovascular diseases despite return to normoglycemia, a phenomenon termed 'glycemic or metabolic memory'. The molecular mechanism underlying this phenomenon remains unclear.

Cardiovascular events, such as myocardial infarction and stroke are caused by atherosclerosis, which is characterized by low grade inflammation of the vascular wall, including accumulation of innate immune cells such as monocytes and macrophages.

The investigators hypothesize that chronic hyperglycemia shifts intracellular metabolism of innate immune cells towards glycolysis and changes the epigenetic state of (progenitors of) innate immune cells (monocytes and macrophages), which reprograms these cells towards a more aggressive, pro-atherogenic phenotype, thereby accelerating atherosclerosis.

In this study, the investigators aim to test this hypothesis. This research will reveal whether the innate immune cells of patients with chronic hyperglycemia show a durable shift in intracellular metabolism and epigenetic changes and whether this associates with vascular inflammation.

Conditions

Interventions

RADIATION

PET-CT (positron emission tomography - computer tomography)

PET-CT to determine vascular inflammation

DIAGNOSTIC_TEST

Blood drawn

Blood drawn

Sponsors & Collaborators

  • European Foundation for the Study of Diabetes

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2019-01-21
Completion
2019-01-21

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03441919 on ClinicalTrials.gov